


**Product Name** : CFT1946  
**Cat. No.** : PC-20593  
**CAS No.** : 2882165-79-7  
**Molecular Formula** : C<sub>45</sub>H<sub>49</sub>F<sub>2</sub>N<sub>11</sub>O<sub>9</sub>S  
**Molecular Weight** : 958.01  
**Target** : PROTAC  
**Solubility** : 10 mM in DMSO



CAS: 2882165-79-7

## Biological Activity

CFT1946 (CFT-1946) is a potent, selective CRBN-based PROTAC degrader of **mutant BRAF**, selectively degrades BRAF V600E (Class I), G469A (Class II), G466V (Class III) mutations and the p61-BRAFV600E splice variant, but not WT BRAF and CRAF.

CFT1946 potently degraded BRAFV600E in A375 cells (DC50=14 nM at 24hr), inhibited ERK phosphorylation (IC50=11nM at 24hr) and cell growth (GI50=94nM at 96hr) while having no effect in the mutant KRAS driven cell line HCT116.

CFT1946 (10 mg/kg PO BID) resulted in deeper tumor regressions in A375 xenografts.

CFT1946 degraded BRAFV600E and caused robust tumor growth inhibition in engineered A375-BRAFV600E/NRASQ61K double mutant model of BRAF inhibitor resistance, caused tumor regressions when combined with the MEK inhibitor, trametinib.

CFT1946, but not Encorafenib (Cat. PC-49770), inhibited proliferation of the BRAFG466V heterozygous lung tumor cell line H1666.

## References

Mathew E. Sowa, et al. *Cancer Res* (2022) 82 (12\_Supplement): 2158.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com